StockData

Liquidia vs United Therapeutics

LQDA and UTHR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LQDA and UTHR compare

United Therapeutics is the larger company, worth 4.9 times as much as Liquidia ($25.1B against $5.1B).

On earnings, United Therapeutics is cheaper: it trades at 20.9× trailing earnings, against 40.8× for Liquidia.

Liquidia grew revenue faster over the last twelve months (2234% versus 2.5% for United Therapeutics).

United Therapeutics keeps more of each dollar of sales as profit, with a net margin of 41.6% compared with 30.7% at Liquidia.

United Therapeutics scores higher on the StockData Score (11 against 8 for Liquidia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLQDAUTHR
Size and price
Market cap$5.1B$25.1B
Share price$56.73$584.10
Change, 1 year102%25.2%
Change, 5 years1280%202%
Beta (5Y)1.000.45
Employees2161,400
StockData Score
Total score811 (better)
Valuation score01 (better)
Growth score22
Performance score35 (better)
Health score33
Dividend score00
Valuation
P/E40.8×20.9× (better)
P/S11.3×7.9× (better)
P/B26.0×3.9× (better)
EV/EBITDA28.2×15.0× (better)
P/FCF33.7×22.9× (better)
PEG–0.91
FCF yield3.0%4.4% (better)
Fair value$32.46$479.23
Margin of safety−74.8%−21.9% (better)
Growth
Revenue growth (TTM)2234% (better)2.5%
Revenue growth, 5Y average192% (better)16.5%
Net income growth (TTM)–5.5%
EPS growth (TTM)–9.0%
EPS growth, 5Y average–19.3%
Profitability
Gross margin–86.1%
Operating margin37.4%44.4% (better)
Net margin30.7%41.6% (better)
FCF margin33.4%34.6% (better)
Return on equity132% (better)19.3%
Return on invested capital–29.7%
Financial health
Interest coverage6.3×117× (better)
Current ratio2.315.73 (better)
Altman Z-score10.4921.67 (better)
Piotroski F-score48 (better)
Dividends and buybacks
Buyback yield–10.0%
Shareholder yield0.00%10.0% (better)
Ownership
Held by institutions81.1%97.4%
Held by insiders19.5%9.1%
Insider net buying, 12 months−$227M (better)−$1.4B
Short interest, % of float24.3%4.7%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.